TWI572713B - Anti-obesity strain of lactic acid bacteria and uses in food and pharmaceutical compositions - Google Patents

Description

Anti-obesity lactic acid bacteria strain and application thereof to food composition and pharmaceutical composition

The present invention relates to a lactic acid bacteria strain and its use in food compositions and pharmaceutical compositions, in particular, an anti-obesity lactic acid bacteria strain and its use in food compositions and pharmaceutical compositions.

Fat is an essential ingredient in the body, but excessive fat can cause damage to the human body. In countries where the national economy is increasingly taking off, the problem of obesity will only increase. Therefore, in the Asian region, China will be the next wave of countries with a sharp increase in obesity.

In addition, Taiwan has become the country with the number one fat in Asia. Among the nationals over 18 years old, the proportion of males who are overweight is 51.1%, and the proportion of women who are overweight is 35.8%, and the proportion is still rising, even overweight. The age group is also declining year by year, and the proportion of overweight among primary and secondary school students has risen to more than 25%, making it the eighth-highest region in the world. Therefore, obesity is an urgent problem to be solved.

Generally, the products containing lactic acid bacteria (LAB) only have the health effect of adjusting the intestinal tract. Although there are tens of thousands of lactic acid bacteria strains in nature, only a few lactic acid strains have been found to have potential accessory traits for absorbing fat. These strains have the ability to resist acid and bile salts, and adsorb intestinal mucus The ability of membrane epithelial cells and their ability to survive after passage through the gastrointestinal tract is an important basis for stimulating the function of the strain in the intestine, absorbing the fat content of the food and screening for strains that promote health effects.

The literature points out that probiotics can maintain the structure and bacterial phase balance of the intestinal flora to promote metabolism, and absorb fat into a part of the bacterial structure, reduce the number of bad bacteria in the body to reduce the obesity caused by the increase in endotoxin concentration. In order to achieve the effect of reducing fat activity.

To date, only a few strains have been confirmed by experimental procedures to have a lactic acid bacteria strain having an activity of absorbing fat. The function of lactic acid bacteria on health is the specificity of the strain rather than the species. The strain that has special effects on human health is called the guidelines for probiotics in food. Report of joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food; London Ontario, Canada April 30 and May 1, 2002: 1-7).

Therefore, the development of functional probiotics with anti-obesity activity is currently a goal.

One of the objects of the present invention is to develop a lactobacillus strain resistant to obesity, wherein anti-obesity may comprise fat loss and/or weight loss.

According to an embodiment of the present invention, the present invention provides an isolated lactic acid bacteria strain which is a strain of Bifidobacterium longum CP-9, which is deposited in the Hsinchu Food Industry Development Research Institute ( FIRDI) is registered as BCRC 910645 and has reduced fat capacity.

According to another embodiment of the present invention, the present invention provides an isolated lactic acid bacteria strain for use as a weight loss, the strain being a Bifidobacterium breve bv-77 strain deposited in the development of Hsinchu Food Industry (FIRDI), registration number BCRC 910533, has the ability to reduce weight.

Another object of the present invention is to develop a food composition and a pharmaceutical composition of an anti-obesity lactic acid bacterium for use as a fat loss or weight loss.

According to another embodiment of the present invention, a pharmaceutical composition for anti-obesity lactic acid bacteria comprising: the above-mentioned reduced-fat/weight-reducing lactic acid bacteria strain and a physiologically acceptable excipient or diluent.

According to another embodiment of the present invention, a food composition for an anti-obesity lactic acid bacterium comprising: the above-described reduced fat/weight loss lactic acid bacteria strain and a physiologically acceptable excipient or diluent.

The purpose, technical contents, features, and effects achieved by the present invention will become more apparent from the detailed description of the appended claims.

Figure 1 is experimental data showing that mice were fed with 10 ¹⁰ CFU (Colony-Forming Units) Bifidobacterium longum CP-9 strains, and the heart weight and cardiac fat weight of the mice after sacrifice dissection.

Figure 2 is a graph showing the change in body weight of weekly weighed mice fed with 10 ¹⁰ CFU (Colony-Forming Units) Bifidobacterium breve bv-77 strain.

Figure 3 is a graph showing experimental changes in body weight after high concentrations of CP-9 and bv-77 powder.

Figure 4 is a graph showing experimental changes in body fat after high concentrations of CP-9 and bv-77 powder.

The freeze-dried culture of the lactic acid bacteria strain of the present invention has been deposited at the Taiwan Food Industry Development Research Institute, and the address is No. 331, Food Road, Hsinchu City, Republic of China. The details of the deposit are shown in Table 1:

Among the two strains of lactic acid bacteria listed in Table 1, Bifidobacterium longum CP-9 has been found to have the ability to reduce fat, including reducing the fat content of the periphery of the organ and absorbing the fat contained in the food to reduce fat intake. . Bifidobacterium breve bv-77 has been found to control animal weight function and alleviate obesity.

The present invention broadly encompasses any of the following biological cultures: Bifidobacterium longum CP-9 strain, Food Industry Development Institute, accession number BCRC 910645, and Bifidobacterium breve bv-77 The strain, Food Industry Development Institute, accession number BCRC 910533, and a food composition or pharmaceutical composition comprising a physiologically acceptable excipient or diluent. The strain of lactic acid bacteria may be an active or inactivated strain.

Wherein, the food composition may include, but is not limited to, a dairy beverage, tea, coffee or a combination thereof. Dairy drinks include fermented milk, yogurt, cheese or milk powder. The pharmaceutical composition may comprise an oral dosage form or an external dosage form; for example, an oral dosage form is a tablet, a capsule, a solution, a powder, and the like.

In the food composition or the pharmaceutical composition, the number of the lactic acid bacteria strain is 10 ⁶ CFU or more; preferably, the number of the lactic acid bacteria strain is 10 ¹⁰ CFU or more.

It is currently known that some strains are effective in reducing the distribution of adipose tissue and reducing the fat content in the diet to reduce intake, but not all Bifidobacterium can have such ability (Yin YN, 2010). For example, McMullen et al. (2006) as to whether probiotics affect hormone and leptin concentrations tested in humans, the plus Bifidobacterium longum with Lactobacillus acidophilus, found that the two strains of this formula to human consumption, There is no effect on the metabolism of hormones and the rise in leptin, so fat accumulation cannot be regulated (McMullen MH, 2006). Such results place more emphasis on the fact that probiotics are indeed strain-specific in their ability to regulate fat distribution or absorb fat.

In fact, it is known from the following findings of the present invention that most Lactobacillus strains do not have the effect of reducing fat and/or reducing body weight. There are only a few literature reports on the study of probiotics related to anti-obesity at home and abroad. It should be noted that the strains requested in this case only contain the Bifidobacterium longum CP-9 strain (registered number BCRC 910645) and the Bifidobacterium breve bv-77 strain (registered number BCRC 910533) deposited at the Hsinchu Food Industry Development Research Institute. Not all Bifidobacterium longum strains or Bifidobacterium breve strains are widely included.

Since fat accumulation, obesity, etc. must be observed in animals, most of the studies are based on animal experiments or human tests.

Example 1: Morphology and general properties of lactic acid bacteria resistant to obesity.

The source of the separation was human breast milk, collected by the mothers in the Tainan area. The taxonomic characteristics of the strains were confirmed based on the 16S rDNA sequence analysis and the results of the API bacterial identification system analysis. The two strains of lactic acid bacteria described in the present invention were found to be Bifidobacterium longum and Bifidobacterium breve, respectively. The morphological and general characteristics of the above strains are detailed in Table 2:

Example 2: Mice were fed once with a high concentration strain, sacrificed 14 days later, and the change in heart fat weight of the mice was observed as compared with the control group.

The reduced-fat lactic acid strain of the present invention, Bifidobacterium longum CP-9 strain BCRC 910645, was used to reduce the weight of the heart-coated fat, which was fed once a high concentration strain, sacrificed after 14 days, dissected and weighed the heart. The weight of the peripheral fat is used to verify the ability of the above strain to reduce fat. The experimental steps are as follows:

1. The experiment is started when the animal is 5 to 6 weeks old.

2. Animals were randomly divided into two groups, one group feeding drinking water and one group feeding mushroom powder water.

3. After the appropriate amount of high-concentration powder is dissolved in water, a feeding dose of 20 mL/kg is administered.

4. Weigh weekly to observe changes in body weight.

5. After two weeks, weighed and sacrificed the animals, taking the fat above the heart, and feeding the powdered water compared to the group of the drinking water.

The statistical analysis of the data is shown in Table 3, Table 4, and Figures 1 and 2, and is expressed as mean ± standard deviation (Mean ± SD). FIG 1 that when the at least 10 ¹⁰ CFU (Colony-Forming Units) Bifidobacterium longum strain mice fed CP-9, and the mice were sacrificed heart weight weight after the cardiac adipose anatomy; FIG. 2 is shown in the experimental data 10 The weight gain of weekly weighing of ¹⁰ CFU (Colony-Forming Units) Bifidobacterium breve bv-77 strain-fed mice. Tables 3 and 4 show changes in body weight and heart and fat weight (means ± SD) of the strains and control groups of the present invention.

Please refer to Table 3. The consumption of general lactic acid bacteria had no significant effect on the body weight of mice. Only Bifidobacterium bv-77 lactic acid bacteria could increase the body weight of mice (a significant difference, Figure 2). Please refer to Figure 2 again, the weight of the first day of the test, the weight of the eighth day of the test and the weight of the fifteenth day of the test, that is, the weight change on the day of sacrifice, the group with the feeding strain bv-77 and the no feeding Compared with the strain group, the increase in the body weight of the mice with the fed strains has a tendency to slow down, and there is a significant difference.

Please refer to Table 4. The mouse is sacrificed and the heart is taken, including the adipose tissue covering the heart, and then the fine membrane of the heart and fat is separated to separate the white adipose tissue for weighing. When the fed strain group was compared with the control group, the heart weights were similar and there was no significant difference. However, the fat weight of the coated heart, the fat weight of the fed strain group was significantly lower than that of the non-feeding group, and the difference had reached a significant difference. This difference indicates that the CP-9 strain has the ability to adjust and reduce the accumulation of fat. It should be noted that other strains do not reduce the accumulation of fat.

Example 3: Anti-obesity lactic acid bacteria were used in human clinical trials.

Lactic acid bacteria should exert the ability to lose weight and reduce fat. First, the health of the gastrointestinal tract must be a necessary condition. The maintenance of the intestinal tract should be excluded, followed by the normal rhythm of the intestinal tract. After the above two problems are excluded, The digestion and absorption of food has an intensive effect, and the body is healthier, and the elimination of intestinal problems is the most powerful function of bifidobacteria. In the initial stage of weight loss, the weight loss is mostly the weight of the intestines or the weight of the accumulated deposits after years of elimination. Then, by using the ability of the strain to effectively absorb fat, the fat in the diet is reduced, and the intake of the human body is decreased. Achieve the purpose of weight loss.

Therefore, the present invention performs a human clinical trial pre-test, except for the Bifidobacterium species which can eliminate intestinal problems, wherein the Bifidobacterium longum strain CP-9 has a lipid-lowering effect, and the Bifidobacterium breve bv-77 strain has a reduced body weight. The role of lactic acid bacteria in reducing weight and reducing fat to achieve anti-obesity effects. Use the following experimental steps:

1. Confirm the tester's body weight and body fat content before starting.

2. The population was divided into two groups, one group was the placebo group, the fruit was oligosaccharide, and the other group was the probiotic group, which was eaten with high-concentration powder (2 x 10 ¹⁰ CFU).

3. After the start of the test, body weight and body fat content were confirmed every 2 to 3 weeks. The measuring machines for body weight and body fat content are all the same.

4. Analysis of changes in body weight and body fat content after one month.

The statistical analysis of the data is shown in Table 5 and Figures 3 and 4. Figure 3 shows the change in body weight; Figure 4 shows the data on changes in body fat, both of which are expressed in Mean ± SD. Figure 3 shows the products provided by the voluntary weight loss patients in a double-blind trial. The volunteers were divided into a placebo group and a probiotic group. The products were given three times a day, half an hour after meals, and lasted for one month. The product contained long doubles. Bifidobacterium CP-9 strain BCRC 910645 and Bifidobacterium breve bv-77 strain BCRC 910533, compared the difference in body weight between the two groups, showing that the changes in body weight of the two groups of volunteers have reached significant differences, the average weight loss of the probiotic group is about Nearly 2 kg / month, while the placebo group increased by nearly 1 kg.

As shown in Figure 4, the body fat content of the two volunteers changed, the probiotic group decreased by nearly 1% body fat, while the placebo group increased by about 0.5% body fat, and this change also showed significant differences, showing Products containing Bifidobacterium longum CP-9 strain BCRC 910645 and Bifidobacterium breve bv-77 strain BCRC 910533 can indeed help improve body fat decline.

Table 5 shows the volunteers who consumed products containing Bifidobacterium longum CP-9 strain BCRC 910645 and Bifidobacterium breve bv-77 strain BCRC 910533 and placebo (the difference between placebo product and probiotic product is placebo product not Changes in body weight and body fat content after Bifidobacterium longum CP-9 strain BCRC 910645 and Bifidobacterium breve bv-77 strain BCRC 910533), the test values are expressed in mean±SD:

Subjects in the probiotic group continued to consume products containing Bifidobacterium longum CP-9 strain BCRC 910645 and Bifidobacterium breve bv-77 strain BCRC 910533 for six months with significant changes in body conditions (not shown). One of the subjects had an average monthly reduction of about 1.67 kg in the case of a normal diet, which was achieved for healthy weight loss.

Through the results of the human clinical trial pretest, the anti-obesity lactic acid bacteria of the present invention can provide a way for the human body to reduce fat intake and achieve the purpose of healthy weight loss. The reduced-fat lactic acid bacteria described in the present invention can simultaneously change the distribution of body fat and reduce the accumulation of body fat. It is an object of the present invention to continue to achieve these desires or at least to provide the public with new options for reducing fat/weight loss purposes. The present invention finds a new fat-reducing lactic acid bacteria that has no side effects and is beneficial to the human body as a new fat-reducing and weight-reducing bacterium. select.

The embodiments described above are only for explaining the technical idea and the features of the present invention, and the purpose of the present invention is to enable those skilled in the art to understand the contents of the present invention and implement them. The scope of the invention is to be construed as being limited by the scope of the invention.

【Biomaterial Storage】

The freeze-dried culture of the lactic acid bacteria strain of the present invention has been deposited at the Taiwan Food Industry Development Research Institute, and the address is No. 331, Food Road, Hsinchu City, Republic of China. The details of the deposit are shown in Table 1:

no

Claims (13)

The use of an isolated lactic acid bacteria strain for preparing a pharmaceutical composition for reducing fat, the strain is Bifidobacterium longum CP-9 strain, and the above strain is deposited in the Hsinchu Food Industry Development Research Institute (FIRDI) registration number For BCRC 910645, it has reduced fat capacity. An isolated lactic acid bacteria strain for preparing a pharmaceutical composition for weight loss, the strain being a Bifidobacterium breve bv-77 strain deposited in the Hsinchu Food Industry Development Research Institute (FIRDI), The registration number BCRC 910533 has a weight reduction capability. The use of a lactic acid bacterium for preparing a pharmaceutical composition for reducing fat or reducing weight comprises: a strain of lactic acid bacteria, which is a Bifidobacterium longum CP-9 strain and a Bifidobacterium breve bv At least one of the -77 strains, the above CP-9 strain is deposited in the Hsinchu Food Industry Development Research Institute (FIRDI) under the accession number BCRC 910645, and has reduced fat capacity; the above bv-77 strain is deposited in the Hsinchu Food Industry Development Research Institute ( FIRDI), accession number BCRC 910533, and having a weight-reducing ability; and a physiologically acceptable excipient or diluent. The use of the lactic acid bacterium according to claim 3 for the preparation of a pharmaceutical composition for reducing fat or reducing weight, wherein the lactic acid bacteria strain is an active strain. The use of the lactic acid bacterium according to claim 3 for the preparation of a pharmaceutical composition for reducing fat or reducing weight, wherein the strain is a combination of a CP-9 strain and a bv-77 strain. The use of the lactic acid bacterium according to claim 3 for the preparation of a pharmaceutical composition for reducing fat or reducing weight, wherein the number of the lactic acid bacteria strain is 10 ¹⁰ CFU or more. A food composition of lactic acid bacteria for use as a fat loss or weight loss, comprising: A strain of lactic acid bacteria, which is at least one of Bifidobacterium longum CP-9 strain and Bifidobacterium breve bv-77 strain, and the above CP-9 strain is deposited in the development of Hsinchu food industry The (FIRDI) deposit number is BCRC 910645 and has reduced fat capacity; the above bv-77 strain is deposited in the Hsinchu Food Industry Development Research Institute (FIRDI), accession number BCRC 910533, and has weight loss capability; and physiologically acceptable Excipient or diluent. The food composition of the lactic acid bacteria according to claim 7, which is used as a fat loss or weight loss, wherein the lactic acid bacteria strain is an active strain. The food composition of the lactic acid bacteria according to claim 7, wherein the lactic acid bacteria strain is a combination of a CP-9 strain and a bv-77 strain. The food composition of the lactic acid bacterium according to claim 7, which is used for fat loss or weight loss, wherein the excipient or diluent is a food. The food composition of the lactic acid bacterium according to claim 10, which is used for fat loss or weight loss, wherein the food product comprises a dairy drink, tea, coffee or a combination thereof. The food composition of the lactic acid bacterium according to claim 11, which is used for fat loss or weight loss, wherein the milk beverage comprises mashed milk, yogurt, cheese or milk powder. The food composition of the lactic acid bacteria according to claim 7, which is used for fat loss or weight loss, wherein the number of the lactic acid bacteria strain is 10 ¹⁰ CFU or more.